Cited by 7,810Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentCancer Treatment and Pharmacology

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Open access

Conroy, Thierry, Desseigne, Françoise, Ychou, Marc, Bouché, Olivier, Guimbaud, Rosine, Bécouarn, Yves, Adenis, Antoine, Raoul, Jean-Luc, Gourgou-Bourgade, Sophie, de la Fouchardière, Christelle, Bennouna, Jaafar, Bachet, Jean-Baptiste, Khemissa-Akouz, Faiza, Péré-Vergé, Denis, Delbaldo, Catherine, Assenat, Eric, Chauffert, Bruno, Michel, Pierre, Montoto-Grillot, Christine, Ducreux, Michel·2011·New England Journal of Medicine

DOI 10.1056/nejmoa1011923

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as compared with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer. METHODS: We randomly assigned 342 patients with an Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating a greater severity of illness) to receive FOLFIRINOX (oxaliplatin, 85 mg per square meter of body-surface area; irinotecan, 180 mg per square meter; leucovorin, 400 mg per square meter; and fluorouracil, 400 mg per square meter given as a bolus followed by 2400 mg per square meter given as a 46-hour continuous infusion, every 2 weeks) or gemcitabine at a dose of 1000 mg per square meter weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks. Six months of chemotherapy were recommended in both groups in patients who had a response. The primary end point was overall survival. RESULTS: The median overall survival was 11.1 months in the FOLFIRINOX group as compared with 6.8 months in the gemcitabine group (hazard ratio for death, 0.57; 95% confidence interval [CI], 0.45 to 0.73; P<0.001). Median progression-free survival was 6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group (hazard ratio for disease progression, 0.47; 95% CI, 0.37 to 0.59; P<0.001). The objective response rate was 31.6% in the FOLFIRINOX group versus 9.4% in the gemcitabine group (P<0.001). More adverse events were noted in the FOLFIRINOX group; 5.4% of patients in this group had febrile neutropenia. At 6 months, 31% of the patients in the FOLFIRINOX group had a definitive degradation of the quality of life versus 66% in the gemcitabine group (hazard ratio, 0.47; 95% CI, 0.30 to 0.70; P<0.001). CONCLUSIONS: As compared with gemcitabine, FOLFIRINOX was associated with a survival advantage and had increased toxicity. FOLFIRINOX is an option for the treatment of patients with metastatic pancreatic cancer and good performance status. (Funded by the French government and others; ClinicalTrials.gov number, NCT00112658.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa1011923

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cancer Statistics, 2010
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pancreatic Cancer
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016

Flagged first, then by citations

Show all 37 references

Research works printed but not linked: 3

Zeghari-Squalli N, 1999, Clin Cancer Res, 5, 1189
10.2307/2281868 · DOI · Paper page
Introduction and methods. In: Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985–1990. Oxford, England: Oxford University Press, 1990.

Sorted by citations

Items 201–300 of 1,032

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
Gonçalvès, A., Gilabert, M., François, É., Dahan, L., Perrier, H., Lamy, R., Ré, D., Largillier, R., Gasmi, M., Tchiknavorian, X., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds135 · Cited by 222
Self-citation
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma
Ko, A. H., LoConte, N. K., Tempero, M. A., Walker, E. J., Kelley, R. K., Lewis, S., Chang, W., Kantoff, E., Vannier, M. W., Catenacci, D. V. T., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000458 · Cited by 226
Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness
Leca, J., Martinez, S., Lac, S., Nigri, J., Secq, V., Rubis, M., Bressy, C., Sergé, A., Lavaut, M., Dusetti, N., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87734 · Cited by 230
Self-citation
Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells
Nielsen, M. F. B., Mortensen, M. B., & Detlefsen, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i9.2678 · Cited by 228
CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma
Noll, E. M., Eisen, C., Stenzinger, A., Espinet, E., Muckenhuber, A., Klein, C., Vogel, V., Klaus, B., Nadler, W. M., Roesli, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4038 · Cited by 228
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
Aglietta, M., Barone, C. A., Sawyer, M. B., Moore, M. J., Miller, W. H., Bagalá, C., Colombi, F., Cagnazzo, C., Gioeni, L., Wang, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu205 · Cited by 221
Advanced-stage pancreatic cancer: therapy options
Werner, J., Combs, S. E., Springfeld, C., Hartwig, W., Hackert, T., & Büchler, M. W. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.66 · Cited by 220
Checkpoint inhibitors in pancreatic cancer
Henriksen, A., Dyhl-Polk, A., Chen, I. M., & Nielsen, D. L. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.06.005 · Cited by 219
Targeting miR-21 for the Therapy of Pancreatic Cancer
Sicard, F., Gayral, M., Lulka, H., Buscail, L., & Cordelier, P. (2013) · Molecular Therapy · doi:10.1038/mt.2013.35 · Cited by 217
Neoadjuvant Treatment in Pancreatic Cancer
Oba, A., Ho, F., Bao, Q. R., Al-Musawi, M. H., Schulick, R. D., & Chiaro, M. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00245 · Cited by 219
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
Weiss, G. J., Blaydorn, L., Beck, J., Bornemann-Kolatzki, K., Urnovitz, H. B., Schütz, E., & Khemka, V. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0525-1 · Cited by 218
Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies
Chiorean, E. G., & Coveler, A. L. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s60328 · Cited by 217
Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer
Groot, V. P., Mosier, S. L., Javed, A. A., Teinor, J. A., Gemenetzis, G., Ding, D., Haley, L. M., Yu, J., Burkhart, R. A., Hasanain, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0197 · Cited by 220
An update on treatment options for pancreatic adenocarcinoma
Lambert, A., Schwarz, L., Borbath, I., Henry, A., Laethem, J. V., Malka, D., Ducreux, M. P., & Conroy, T. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919875568 · Cited by 222
Self-citation
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
Kunzmann, V., Siveke, J. T., Algül, H., Goekkurt, E., Siegler, G. M., Martens, U. M., Waldschmidt, D., Pelzer, U., Fuchs, M., Kullmann, F., et al. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30330-7 · Cited by 214
Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma
Mahaseth, H., Brutcher, E., Kauh, J. S. W., Hawk, N. N., Kim, S., Chen, Z., Kooby, D. A., Maithel, S. K., Landry, J. C., & El‐Rayes, B. F. (2013) · Pancreas · doi:10.1097/mpa.0b013e31829e2006 · Cited by 208
Treatment landscape of metastatic pancreatic cancer
Dosso, S. D., Siebenhüner, A. R., Winder, T., Meisel, A., Fritsch, R., Astaras, C., Szturz, P., & Borner, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102180 · Cited by 212
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer
Stein, S., James, E. S., Deng, Y., Cong, X., Kortmansky, J. S., Li, J., Staugaard, C., Doddamane, I., Boustani, A. M., Patel, V. V., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.45 · Cited by 209
Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment
Looi, C.-K., Chung, F. F., Leong, C., Wong, S. F., Rosli, R., & Mai, C. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1153-8 · Cited by 209
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer
Stoop, T. F., Theijse, R. T., Seelen, L. W. F., Koerkamp, B. G., van Eijck, C. H. J., Wolfgang, C. L., van Tienhoven, G., van Santvoort, H. C., Molenaar, I. Q., Wilmink, J. W., et al. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00856-2 · Cited by 215
Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era
Morton, L. M., Dores, G. M., Schonfeld, S. J., Linet, M. S., Sigel, B. S., Lam, C. J. K., Tucker, M. A., & Curtis, R. E. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5625 · Cited by 204
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives
Perkhofer, L., Gout, J., Roger, É., de Almeida, F. K., Simões, C., Wiesmüller, L., Seufferlein, T. T. W., & Kleger, A. (2020) · Gut · doi:10.1136/gutjnl-2019-319984 · Cited by 207
A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes
Boursi, B., Finkelman, B., Giantonio, B. J., Haynes, K., Rustgi, A. K., Rhim, A. D., Mamtani, R., & Yang, Y.-X. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.046 · Cited by 202
Graviola: A novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism
Torres, M. P., Rachagani, S., Purohit, V., Pandey, P., Joshi, S., Moore, E. D., Johansson, S. L., Singh, P. K., Ganti, A. K., & Batra, S. K. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.031 · Cited by 202
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 208
Inflammatory networks and immune surveillance of pancreatic carcinoma
Vonderheide, R. H., & Bayne, L. J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.01.006 · Cited by 204
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
Noel, M., O’Reilly, E. M., Wolpin, B. M., Ryan, D. P., Bullock, A. J., Britten, C. D., Linehan, D. C., Belt, B. A., Gamelin, E. C., Ganguly, B., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00830-3 · Cited by 199
Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: A randomised clinical trial on overall survival
Tröger, W., Galun, D. A., Reif, M., Schumann, A., Stanković, N., & Milicevic, M. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.043 · Cited by 199
Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer
Heßmann, E., Patzak, M. S., Klein, L., Chen, N., Kari, V., Ramu, I., Bapiro, T. E., Frese, K. K., Gopinathan, A., Richards, F. M., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-311954 · Cited by 205
Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma
Xie, Y., Zhu, S., Zhong, M., Yang, M., Sun, X., Liu, J., Kroemer, G., Lotze, M. T., Zeh, H. J., Kang, R., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.07.036 · Cited by 201
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
Borad, M. J., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7504 · Cited by 197
Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC)
Neuzillet, C., Gaujoux, S., Williet, N., Bachet, J., Bauguion, L., Durand, L. C., Conroy, T., Dahan, L., Gilabert, M., Huguet, F., et al. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.08.008 · Cited by 222
Self-citation
Diagnosis and management of pancreatic cancer
Kanji, Z. S., & Gallinger, S. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.121368 · Cited by 196
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
Kamath, S. D., Kalyan, A., Kircher, S. M., Nimeiri, H. S., Fought, A. J., Benson, A. B., & Mulcahy, M. F. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0473 · Cited by 200
Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer
Xiong, G., Liu, C., Yang, G., Feng, M., Xu, J., Zhao, F., You, L., Zhou, L., Zheng, L., Hu, Y., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0777-7 · Cited by 195
Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer
Cuneo, K. C., Morgan, M. A., Sahai, V., Schipper, M. J., Parsels, L. A., Parsels, J. D., Devasia, T. P., Al-Hawaray, M., Cho, C. S., Nathan, H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00730 · Cited by 197
New biomarkers and targets in pancreatic cancer and their application to treatment
Costello, E., Greenhalf, W., & Neoptolemos, J. P. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.119 · Cited by 192
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
Kindler, H. L., Richards, D., Garbo, L. E., Garon, E. B., Stephenson, J., Rocha‐Lima, C., Safran, H. P., Chan, D., Kocs, D. M., Galimi, F., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds142 · Cited by 192
Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer
Boone, B. A., Steve, J., Krasinskas, A. M., Zureikat, A. H., Lembersky, B. C., Gibson, M. K., Stoller, R. G., Zeh, H. J., & Bahary, N. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23392 · Cited by 191
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study
Mahalingam, D., Wilkinson, G., Eng, K. H., Fields, P., Raber, P. L., Moseley, J. L., Cheetham, K., Coffey, M. C., Nuovo, G. J., Kaliński, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2078 · Cited by 193
Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?
He, J. P., Blair, A. B., Groot, V. P., Javed, A. A., Burkhart, R. A., Gemenetzis, G., Hruban, R. H., Waters, K. M., Poling, J., Zheng, L., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002672 · Cited by 194
Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?
Christians, K. K., Tsai, S., Mahmoud, A., Ritch, P. S., Thomas, J. P., Wiebe, L. A., Kelly, T. R., Erickson, B. A., Wang, H., Evans, D. B., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0273 · Cited by 188
Onivyde for the therapy of multiple solid tumors
Zhang, H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105587 · Cited by 188
Current standards and new innovative approaches for treatment of pancreatic cancer
Conroy, T., Bachet, J., Ayav, A., Huguet, F., Lambert, A., Caramella, C., Maréchal, R., Laethem, J. V., & Ducreux, M. P. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.026 · Cited by 193
Self-citation
Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma
Latenstein, A. E. J., van der Geest, L. G., Bonsing, B. A., Koerkamp, B. G., Mohammad, N. H., de Hingh, I. H. J. T., de Meijer, V. E., Molenaar, I. Q., van Santvoort, H. C., van Tienhoven, G., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.002 · Cited by 192
Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy
Zins, M., Matos, C., & Cassinotto, C. (2018) · Radiology · doi:10.1148/radiol.2018171670 · Cited by 188
Desmoplasia and Chemoresistance in Pancreatic Cancer
Schober, M., Jesenofsky, R., Faissner, R., Weidenauer, C., Hagmann, W., Michl, P., Heuchel, R. L., Haas, S., & Löhr, M. J. (2014) · Cancers · doi:10.3390/cancers6042137 · Cited by 190
Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas
Katz, M. H. G., Ou, F., Herman, J. M., Ahmad, S. A., Wolpin, B. W., Marsh, R., Behr, S. C., Shi, Q., Chuong, M. D., Schwartz, L. H., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3441-z · Cited by 188
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
Rougier, P. R., Riess, H. B., Manges, R., Karásek, P., Humblet, Y., Barone, C., Santoro, A., Assadourian, S., Hatteville, L., & Philip, P. A. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.002 · Cited by 183
FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer
Petrelli, F., Coinu, A., Borgonovo, K., Cabiddu, M., Ghilardi, M., Lonati, V., Aitini, E., & Barni, S. (2015) · Pancreas · doi:10.1097/mpa.0000000000000314 · Cited by 182
Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials
Petrelli, F., Comito, T., Ghidini, A., Torri, V., Scorsetti, M., & Barni, S. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.10.030 · Cited by 182
Borderline resectable pancreatic cancer: Definitions and management
Lopez, N. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i31.10740 · Cited by 181
A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer
Kim, E. J.-H., Ben‐Josef, E., Herman, J. M., Bekaii‐Saab, T., Dawson, L. A., Griffith, K. A., Francis, I. R., Greenson, J. K., Simeone, D. M., Lawrence, T. S., et al. (2013) · Cancer · doi:10.1002/cncr.28117 · Cited by 180
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
Portal, A., Pernot, S., Tougeron, D., Arbaud, C., Bidault, A. T., de la Fouchardière, C., Hammel, P. R., Lecomte, T., Dréanic, J., Coriat, R., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.328 · Cited by 184
Self-citation
Molecular and cellular mechanisms of chemoresistance in pancreatic cancer
Adamska, A., Elaskalani, O., Emmanouilidi, A., Kim, M. K., Razak, N. B. A., Metharom, P., & Falasca, M. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.11.007 · Cited by 186
FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort
Marthey, L., Cunha, A. S., Blanc, J., Gauthier, M., Cueff, A., François, É., Trouilloud, I., Malka, D., Bachet, J., Coriat, R., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3898-9 · Cited by 179
Self-citation
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Shroff, R. T., Hendifar, A. E., McWilliams, R. R., Geva, R., Epelbaum, R., Rolfe, L., Goble, S. M., Lin, K., Biankin, A. V., Giordano, H., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00316 · Cited by 183
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
Schram, A. M., Odintsov, I., Espinosa-Cotton, M., Khodos, I., Sisso, W. J., Mattar, M. S., Lui, A. J. W., Vojnic, M., Shameem, S. H., Chauhan, T., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1119 · Cited by 178
Survival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177
Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis
Tachezy, M., Gebauer, F., Janot, M., Uhl, W. H., Zerbi, A., Montorsi, M., Périnel, J., Adham, M., Dervenis, C., Agalianos, C., et al. (2016) · Surgery · doi:10.1016/j.surg.2016.02.019 · Cited by 177
Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial
Liu, Y., Guo, Y., Wu, Z., Feng, K., Tong, C., Wang, Y., Dai, H., Shi, F., Yang, Q., & Han, W. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.04.088 · Cited by 179
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial
Chung, V., McDonough, S., Philip, P. A., Cardin, D., Wang-Gillam, A., Hui, L., Tejani, M. A., Seery, T. E., Dy, I. A., Al Baghdadi, T., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5383 · Cited by 176
Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery
Muggia, F. M., Bonetti, A. V., Hoeschele, J. D., Rozencweig, M., & Howell, S. B. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.7481 · Cited by 181
Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer
Rombouts, S. J. E., Vogel, J. A., van Santvoort, H. C., van Lienden, K. P., van Hillegersberg, R., Busch, O. R., Besselink, M. G., & Molenaar, I. Q. (2014) · British journal of surgery · doi:10.1002/bjs.9716 · Cited by 179
Pancreatic cancer: advances in treatment.
Mohammed, S., Buren, G. V., & Fisher, W. E. (2014) · PubMed Central · doi:10.3748/wjg.v20.i28.9354 · Cited by 175
The stromal compartments in pancreatic cancer: Are there any therapeutic targets?
Lunardi, S., Muschel, R. J., & Brunner, T. B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.09.039 · Cited by 178
Pancreatic Cancer Epidemiology, Detection, and Management
Zhang, Q., Zeng, L., Chen, Y., Lian, G., Qian, C., Chen, S., Li, J., & Huang, K. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/8962321 · Cited by 175
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
Kabacaoğlu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01878 · Cited by 181
Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results
Reyngold, M., Parikh, P. J., & Crane, C. H. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1309-x · Cited by 178
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
Jesus‐Acosta, A. D., Sugar, E. A., O'Dwyer, P. J., Ramanathan, R. K., Hoff, D. D. V., Rasheed, Z. A., Zheng, L., Begum, A., Anders, R. A., Maitra, A., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0683-3 · Cited by 178
What We Have Learned About Pancreatic Cancer From Mouse Models
Pérez-Mancera, P. A., Guerra, C. E., Barbacid, M., & Tuveson, D. A. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.03.002 · Cited by 178
Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer
Nishiwada, S., Sho, M., Yasuda, S., Shimada, K., Yamato, I., Akahori, T., Kinoshita, S., Nagai, M., Konishi, N., & Nakajima, Y. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0144-7 · Cited by 173
Pancreas Cancer-Associated Weight Loss
Hendifar, A. E., Petzel, M. Q. B., Zimmers, T. A., Denlinger, C. S., Matrisian, L. M., Picozzi, V. J., & Rahib, L. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0266 · Cited by 178
Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy
Sleightholm, R. L., Neilsen, B. K., Li, J., Steele, M. M., Singh, R. K., Hollingsworth, M. A., & Oupický, D. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.012 · Cited by 171
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
Perri, G., Prakash, L., Qiao, W., Varadhachary, G. R., Wolff, R. A., Fogelman, D. R., Overman, M. J., Pant, S., Javle, M. M., Koay, E. J., et al. (2020) · JAMA Surgery · doi:10.1001/jamasurg.2020.2286 · Cited by 173
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
for the Dutch Pancreatic Cancer Group, Janssen, Q. P., van Dam, J. L., Bonsing, B. A., Bos, H., Bosscha, K. P., Coene, P. P. L. O., van Eijck, C. H. J., de Hingh, I. H. J. T., Karsten, T. M., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08031-z · Cited by 171
Phase II study of FOLFIRINOX for chemotherapy‐naïve Japanese patients with metastatic pancreatic cancer
Okusaka, T., Ikeda, M., Fukutomi, A., Ioka, T., Furuse, J., Ohkawa, S., Isayama, H., & Boku, N. (2014) · Cancer Science · doi:10.1111/cas.12501 · Cited by 172
An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study
Nakamura, K., Zhu, Z., Roy, S., Jun, E., Han, H., Muñoz, R. M., Nishiwada, S., Sharma, G. G., Cridebring, D., Zenhausern, F., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.06.090 · Cited by 174
Visceral Adiposity and Sarcopenic Visceral Obesity are Associated with Poor Prognosis After Resection of Pancreatic Cancer
Okumura, S., Kaido, T., Hamaguchi, Y., Kobayashi, A., Shirai, H., Yao, S., Yagi, S., Kamo, N., Hatano, E., Okajima, H., et al. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-6077-y · Cited by 171
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial
Fuchs, C. S., Azevedo, S. J., Okusaka, T., Laethem, J. V., Lipton, L. R., Riess, H. B., Szczylik, C. A., Moore, M. J., Peeters, M., Bodoky, G., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv027 · Cited by 168
Barriers and opportunities in pancreatic cancer immunotherapy
Ju, Y., Xu, D., Liao, M.-M., Sun, Y., Bao, W.-D., Yao, F., & Ma, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00681-z · Cited by 174
A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma
Lytle, N. K., Ferguson, L. P., Rajbhandari, N., Gilroy, K. L., Fox, R. G., Deshpande, A. J., Schürch, C. M., Hamilton, M., Robertson, N., Lin, W., et al. (2019) · Cell · doi:10.1016/j.cell.2019.03.010 · Cited by 166
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma
Noonan, A. M., Farren, M. R., Geyer, S. M., Huang, Y., Tahiri, S., Ahn, D., Mikhail, S., Ciombor, K. K., Pant, S., Aparo, S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.66 · Cited by 166
Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer
Hartwig, W., Gluth, A., Hinz, U., Koliogiannis, D., Strobel, O., Hackert, T., Werner, J., & Büchler, M. W. (2016) · British journal of surgery · doi:10.1002/bjs.10221 · Cited by 165
Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule
Marchetti, C., Zyner, K. G., Ohnmacht, S. A., Robson, M. P., Haider, S. M., Morton, J. P., Marsico, G., Vo, T. D., Laughlin, S., Ahmed, A. A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01781 · Cited by 168
Leukocyte heterogeneity in pancreatic ductal adenocarcinoma: phenotypic and spatial features associated with clinical outcome
Liudahl, S. M., Betts, C. B., Sivagnanam, S., Morales-Oyarvide, V., da Silva, A., Yuan, C., Hwang, S., Grossblatt-Wait, A., Leis, K. R., Larson, W., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0841 · Cited by 164
Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer
Takahashi, H., Ohigashi, H., Gotoh, K., Marubashi, S., Yamada, T., Murata, M., Ioka, T., Uehara, H., Yano, M., & Ishikawa, O. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31829b3ce4 · Cited by 164
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
Bournet, B., Buscail, C., Muscari, F., Cordelier, P., & Buscail, L. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.012 · Cited by 173
Strategies for Increasing Pancreatic Tumor Immunogenicity
Johnson, B. A., Yarchoan, M. M., Lee, V., Laheru, D. A., & Jaffee, E. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2318 · Cited by 166
Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
Gori, S., Inno, A., Belluomini, L., Bocus, P., Bisoffi, Z., Russo, A. D., & Arcaro, G. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.09.003 · Cited by 164
Pancreatic Adenocarcinoma: Treating a Systemic Disease With Systemic Therapy
Sohal, D. P. S., Walsh, R. M., Ramanathan, R. K., & Khorana, A. A. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju011 · Cited by 163
Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists
Beatty, G. L., Li, Y., & Long, K. B. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1270208 · Cited by 163
Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study
Ruarus, A. H., Vroomen, L. G. P. H., Geboers, B., van Veldhuisen, E., Puijk, R. S., Nieuwenhuizen, S., Besselink, M. G., Zonderhuis, B. M., Geert Kazemier, M., de Gruijl, T. D., et al. (2019) · Radiology · doi:10.1148/radiol.2019191109 · Cited by 162
Management of pancreatic cancer in the elderly
Higuera, O. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.764 · Cited by 164
Drug independence and the curability of cancer by combination chemotherapy
Pomeroy, A. E., Schmidt, E. V., Sorger, P. K., & Palmer, A. C. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.06.009 · Cited by 161
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
Ko, A. H., Tempero, M. A., Shan, Y.-S., Su, W., Lin, Y.-L., Dito, E., Ong, A., Wang, Y.-W., Yeh, C. G., & Chen, L.-T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.408 · Cited by 160
Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
Ueno, H., Ikeda, M., Ueno, M., Mizuno, N., Ioka, T., Omuro, Y., Nakajima, T. E., & Furuse, J. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2972-3 · Cited by 161
Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development
Dreyer, S. B., Chang, D. K.-F., Bailey, P. J., & Biankin, A. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2411 · Cited by 168
Stromal Modulation and Treatment of Metastatic Pancreatic Cancer with Local Intraperitoneal Triple miRNA/siRNA Nanotherapy
Xie, Y., Yu, H., Wang, Y., Sleightholm, R. L., Prajapati, D. R., Bader, J., Yu, A., Tang, W., Jaramillo, L., Li, J., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b03978 · Cited by 162
Regulation and function of autophagy in pancreatic cancer
Li, J., Chen, X., Kang, R., Zeh, H. J., Klionsky, D. J., & Tang, D. (2020) · Autophagy · doi:10.1080/15548627.2020.1847462 · Cited by 167

Authors: Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., Bennouna, J., Bachet, J.-B., Khemissa-Akouz, F., Péré-Vergé, D., Delbaldo, C., Assenat, E., Chauffert, B., Michel, P., Montoto-Grillot, C., & Ducreux, M.
Affiliations: Centre Léon Bérard (FR)
Centre Hospitalier Universitaire de Reims (FR)
Institut Claudius Regaud (FR)
Institut Bergonié (FR)
Centre Oscar Lambret (FR)
Centre Eugène Marquis (FR)
Hôpital Ambroise-Paré (FR)
Centre Hospitalier de Perpignan (FR)
Hôpital de la Croix-Rousse (FR)
Centre Hospitalier Universitaire Henri-Mondor (FR)
Centre Georges François Leclerc (FR)
Université de Rouen Normandie (FR)
UniCancer Group (FR)
Institut Gustave Roussy (FR)
ORCID: Conroy, Thierry
Ychou, Marc
Bouché, Olivier
Guimbaud, Rosine
Adenis, Antoine
Raoul, Jean-Luc
Bennouna, Jaafar
Bachet, Jean-Baptiste
Khemissa-Akouz, Faiza
Michel, Pierre
Montoto-Grillot, Christine
Ducreux, Michel
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2011-05-12
Volume: 364
Issue: 19
Pages: 1817-1825
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1011923
OpenAlex: W2151253787
Cited by: 7,810
References: 37
Citations by year: 2026: 425 · 2025: 521 · 2024: 560 · 2023: 604 · 2022: 622 · 2021: 785 · 2020: 692 · 2019: 563 · 2018: 577 · 2017: 558 · 2016: 454 · 2015: 473 · 2014: 388 · 2013: 282 · 2012: 222
FWCI: 150.63
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords: FOLFIRINOX, gemcitabine, metastatic pancreatic cancer, first-line chemotherapy, oxaliplatin, irinotecan, 5-fluorouracil, leucovorin, overall survival, progression-free survival, objective response rate, febrile neutropenia, quality of life, adverse events, combination chemotherapy, randomized trial comparison
MeSH terms: Irinotecan, Oxaliplatin, Gemcitabine, Adenocarcinoma, Adult, Aged, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Deoxycytidine, Female, Fluorouracil, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Pancreatic Neoplasms, Quality of Life, Severity of Illness Index, Proportional Hazards Models, Survival Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks